Using real world data to bridge the evidence gap left by prostate cancer screening trials
This analysis of high-quality RWD estimates a 79% decrease in harm from the diagnostic process when comparing the previous pathway to actual outcomes from current UK clinical practice. This confirms and quantifies the harm reduction delivered by new diagnostic techniques.
Authors
- Amy Rylance (ORCID: https://orcid.org/0009-0004-7792-804X)
- Taimur T. Shah (ORCID: https://orcid.org/0000-0003-1642-1208)
- Natalia Norori (ORCID: https://orcid.org/0000-0002-6611-118X)
- N. Burns-Cox
- M.D. Hobbs
- Nikhil Mayor (ORCID: https://orcid.org/0000-0003-2681-2501)
- L. Blaney
- Antonio Naranjo (ORCID: https://orcid.org/0000-0002-2013-6664)
Institutions
- Taunton & Somerset NHS Foundation Trust (GB)
- Bristol Clinical Commissioning Group (GB)
- Prostate Cancer UK (GB)
- Imperial College London (GB)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1016/j.esmorw.2024.100073
- Citations
- 2
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Prostate Cancer UK
- Urology Foundation